Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures
Open Access
- 14 December 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (2)
Abstract
We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV) treatment, in primary sclerosing cholangitis associated inflammatory bowel disease (PSC-IBD); NCT05376228. Fifteen patients with PSC and active colitis (median faecal calprotectin 459µg/g; median total Mayo score 5) were treated with OV (125mg QID) for 4 weeks and followed-up for a further 4 weeks of treatment withdrawal (8 weeks, end-of-study). Colonic biopsies were obtained at baseline and week 4. Clinical assessments, and serum and stool samples (metagenomics, metatranscriptomics and metabolomics) were collected at weeks 0, 2, 4 and 8. The primary efficacy outcome measure was induction of clinical remission. OV resulted in clinical remission in 12/15 patients and significant reductions in faecal calprotectin. OV was associated with reduced abundances of Lachnospiraceae, genera Blautia and Bacteroides; and enrichment of Enterobacteriaceae, and genera Veillonella, Akkermansia and Escherichia. OV treatment was associated with downregulation of multiple metatranscriptomic pathways (including short chain fatty acid [SCFA] metabolism and bile acid [BA] biotransformation), along with host genes and multiple pathways involved in inflammatory responses and antimicrobial defence; and an upregulation of genes associated with extracellular matrix repair. OV use resulted in loss of specific faecal SCFAs and secondary BAs, including lithocholic acid derivatives. Colitis activity relapsed following OV withdrawal, with host mucosal and microbial changes trending towards baseline. Four weeks of OV induces remission in PSC-IBD activity, associated with a reduction in gut bacterial diversity and compositional changes relating to BA and SCFA homeostasis.Keywords
Funding Information
- Medical Research Council
- National Institute for Health Research (MC_PC_12025)
- UK Consortium for MetAbolic Phenotyping
- National Institute for Health Research
- Imperial Biomedical Research Centre
This publication has 83 references indexed in Scilit:
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #Hepatology, 2009
- A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allograftsLiver Transplantation, 2009
- ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networksBioinformatics, 2009
- Long‐term Treatment of Primary Sclerosing Cholangitis in Children With Oral Vancomycin: An Immunomodulating AntibioticJournal of Pediatric Gastroenterology and Nutrition, 2008
- Visualization of GC/TOF-MS-Based Metabolomics Data for Identification of Biochemically Interesting Compounds Using OPLS Class ModelsAnalytical Chemistry, 2007
- A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysisThe Analyst, 2006
- XCMS: Processing Mass Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching, and IdentificationAnalytical Chemistry, 2006
- Oral Vancomycin: Treatment of Primary Sclerosing Cholangitis in Children with Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 1998
- Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis.Gut, 1985